Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin for Face Perception in Congenital Prosopagnosia
NCT02091817Phase 1Suspended
- Sponsor
- Soroka University Medical Center
- Start
- Nov 2013
- Primary completion
- Dec 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of oxytocin in congenital prosopagnosia (DP) (2 arms), sponsored by Soroka University Medical Center. Primary endpoint: Memory performance at Day 2. Started Nov 2013; status: suspended.
02
Drugs
oxytocin
03
Conditions
congenital prosopagnosia (DP)
Beyond the preview
Go deeper on NCT02091817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02091817.